Thoms, Kai-Martin

[["dc.bibliographiccitation.firstpage","1085"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Carcinogenesis"],["dc.bibliographiccitation.lastpage","1090"],["dc.bibliographiccitation.volume","26"],["dc.contributor.author","Blankenburg, S."],["dc.contributor.author","Konig, I. R."],["dc.contributor.author","Moessner, R."],["dc.contributor.author","Laspe, Petra"],["dc.contributor.author","Thoms, Kai Martin"],["dc.contributor.author","Krueger, Ulrich"],["dc.contributor.author","Khan, Sajjad"],["dc.contributor.author","Westphal, G."],["dc.contributor.author","Berking, Carola"],["dc.contributor.author","Volkenandt, Matthias"],["dc.contributor.author","Reich, Kristian"],["dc.contributor.author","Neumann, C."],["dc.contributor.author","Ziegler, Andreas"],["dc.contributor.author","Kraemer, Kenneth H."],["dc.contributor.author","Emmert, Steffen"],["dc.date.accessioned","2018-11-07T10:29:15Z"],["dc.date.available","2018-11-07T10:29:15Z"],["dc.date.issued","2005"],["dc.description.abstract","Individuals with the rare DNA repair deficiency syndrome xeroderma pigmentosum (XP) are sensitive to the sun and exhibit a 1000-fold increased risk for developing skin cancers, including cutaneous melanoma. Inherited polymorphisms of XP genes may contribute to subtle variations in DNA repair capacity and genetic susceptibility to melanoma. We investigated the role of three polymorphic alleles of the DNA repair gene XPC in a hospital-based case-control study of 294 Caucasian patients from Germany who had cutaneous melanoma and 375 healthy cancer-free sex-matched Caucasian control subjects from the same area. We confirmed that the XPC intron 9 PAT+, intron 11 -6A, and the exon 15 2920C polymorphisms are in a linkage disequilibrium. Only 1.6% of the 669 donors genotyped were discordant for these three polymorphisms. The allele frequencies (cases: controls) were for intron 9 PAT+ 41.7%:36.9%, for intron 11 -6A 41.8%:37.0% and for exon 15 2920C 41.3%:37.3%. Using multivariate logistic regression analyses to control for age, skin type and number of nevi, the three polymorphisms were significantly associated with increased risks of melanoma: OR 1.87 (95% CI: 1.10-3.19; P = 0.022), OR 1.83 (95% CI: 1.07-3.11; P = 0.026), and OR 1.82 (95% CI: 1.07-3.08; P = 0.026), respectively. Exploratory multivariate analyses of distinct subgroups revealed that these polymorphisms were associated with increased risks for the development of multiple primary melanomas (n = 28). The results of our case-control study support the hypothesis that the intron 9 PAT+, intron 11 -6A and exon 15 2920C haplotype may contribute to the risk of developing cutaneous melanoma by increasing the rate of an alternatively spliced XPC mRNA isoform that skips exon 12 and leads to reduced DNA repair. Our results should be validated in independent samples in order to guard against false positive findings."],["dc.description.sponsorship","Intramural NIH HHS [Z01 BC004517-31]"],["dc.identifier.doi","10.1093/carcin/bgi055"],["dc.identifier.isi","000229700100008"],["dc.identifier.pmid","15731165"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/43601"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Oxford Univ Press"],["dc.relation.issn","0143-3334"],["dc.title","Assessment of 3 xeroderma pigmentosum group C gene polymorphisms and risk of cutaneous melanoma: a case-control study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","3359"],["dc.bibliographiccitation.issue","13"],["dc.bibliographiccitation.journal","Cancers"],["dc.bibliographiccitation.volume","13"],["dc.contributor.affiliation","Koch, Elias; \t\t \r\n\t\t Department of Dermatology, Universitätsklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany, elias.koch@uk-erlangen.de\t\t \r\n\t\t Comprehensive Cancer Center Erlangen-European Metropolitan Area of Nuremberg (CCC ER-EMN), 91054 Erlangen, Germany, elias.koch@uk-erlangen.de"],["dc.contributor.affiliation","Petzold, Anne; \t\t \r\n\t\t Department of Dermatology, Universitätsklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany, Anne.Petzold@uk-erlangen.de\t\t \r\n\t\t Comprehensive Cancer Center Erlangen-European Metropolitan Area of Nuremberg (CCC ER-EMN), 91054 Erlangen, Germany, Anne.Petzold@uk-erlangen.de"],["dc.contributor.affiliation","Wessely, Anja; \t\t \r\n\t\t Department of Dermatology, Universitätsklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany, Anja.Wessely@uk-erlangen.de\t\t \r\n\t\t Comprehensive Cancer Center Erlangen-European Metropolitan Area of Nuremberg (CCC ER-EMN), 91054 Erlangen, Germany, Anja.Wessely@uk-erlangen.de"],["dc.contributor.affiliation","Dippel, Edgar; \t\t \r\n\t\t Department of Dermatology, Ludwigshafen Medical Center, 67059 Ludwigshafen, Germany, dippele@klilu.de"],["dc.contributor.affiliation","Gesierich, Anja; \t\t \r\n\t\t Department of Dermatology, University Hospital Würzburg, 97080 Würzburg, Germany, gesierich_a@ukw.de"],["dc.contributor.affiliation","Gutzmer, Ralf; \t\t \r\n\t\t Skin Cancer Center Minden, Department of Dermatology, Mühlenkreiskliniken AöR, Ruhr University Bochum Campus Minden, 32423 Minden, Germany, Ralf.Gutzmer@ruhr-uni-bochum.de"],["dc.contributor.affiliation","Hassel, Jessica; \t\t \r\n\t\t Skin Cancer Center, Department of Dermatology and National Center for Tumor Diseases (NCT), University Hospital Heidelberg, 69120 Heidelberg, Germany, Jessica.Hassel@med.uni-heidelberg.de"],["dc.contributor.affiliation","Haferkamp, Sebastian; \t\t \r\n\t\t Department of Dermatology, University Hospital Regensburg, 93053 Regensburg, Germany, sebastian.haferkamp@ukr.de"],["dc.contributor.affiliation","Hohberger, Bettina; \t\t \r\n\t\t Department of Ophthalmology, Universitätsklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany, Bettina.Hohberger@uk-erlangen.de"],["dc.contributor.affiliation","Kähler, Katharina; \t\t \r\n\t\t Department of Dermatology, University Hospital Schleswig-Holstein, Campus Kiel, 24105 Kiel, Germany, kckaehler@yahoo.de"],["dc.contributor.affiliation","Knorr, Harald; \t\t \r\n\t\t Department of Ophthalmology, Universitätsklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany, Harald.Knorr@uk-erlangen.de"],["dc.contributor.affiliation","Kreuzberg, Nicole; \t\t \r\n\t\t Department of Dermatology and Venereology, Skin Cancer Center at the Center of Integrated Oncology (CIO) Köln Bonn, University Hospital of Cologne, 50937 Cologne, Germany, nicole.kreuzberg@uk-koeln.de"],["dc.contributor.affiliation","Leiter, Ulrike; \t\t \r\n\t\t Department of Dermatology, Center for Dermatooncology, University Hospital Tübingen, 72056 Tübingen, Germany, Ulrike.Leiter@med.uni-tuebingen.de"],["dc.contributor.affiliation","Loquai, Carmen; \t\t \r\n\t\t Department of Dermatology, University Medical Center Mainz, 55131 Mainz, Germany, carmen.loquai@unimedizin-mainz.de"],["dc.contributor.affiliation","Meier, Friedegund; \t\t \r\n\t\t Skin Cancer Center at the University Cancer Centre Dresden and National Center for Tumor Diseases & Department of Dermatology, University Hospital Carl Gustav Carus, 01307 Dresden, Germany, Friedegund.Meier@uniklinikum-dresden.de"],["dc.contributor.affiliation","Meissner, Markus; \t\t \r\n\t\t Department of Dermatology, Venereology and Allergology, Goethe University, 60590 Frankfurt am Main, Germany, markus.meissner@kgu.de"],["dc.contributor.affiliation","Mohr, Peter; \t\t \r\n\t\t Department of Dermatology, Elbeklinikum, 21614 Buxtehude, Germany, peter.mohr@elbekliniken.de"],["dc.contributor.affiliation","Pföhler, Claudia; \t\t \r\n\t\t Department of Dermatology, Saarland University Medical School, 66421 Homburg/Saar, Germany, claudia.pfoehler@uks.eu"],["dc.contributor.affiliation","Rahimi, Farnaz; \t\t \r\n\t\t Department of Dermatology and Allergy, Munich University Hospital (LMU), 81377 Munich, Germany, Farnaz.Rahimi@med.uni-muenchen.de"],["dc.contributor.affiliation","Schadendorf, Dirk; \t\t \r\n\t\t Department of Dermatology, University Hospital Essen, University Duisburg-Essen, 45147 Essen, Germany, Dirk.Schadendorf@uk-essen.de\t\t \r\n\t\t German Cancer Consortium, Partner Site Essen, 45147 Essen, Germany, Dirk.Schadendorf@uk-essen.de"],["dc.contributor.affiliation","Schell, Beatrice; \t\t \r\n\t\t Department of Dermatology, SRH Wald-Klinikum Gera, 07548 Gera, Germany, Beatrice.Schell@srh.de"],["dc.contributor.affiliation","Schlaak, Max; \t\t \r\n\t\t Department of Dermatology, Venerology and Allergology, Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, 10117 Berlin, Germany, max.schlaak@charite.de"],["dc.contributor.affiliation","Terheyden, Patrick; \t\t \r\n\t\t Department of Dermatology, University of Lübeck, 23562 Lübeck, Germany, patrick.terheyden@uksh.de"],["dc.contributor.affiliation","Thoms, Kai-Martin; \t\t \r\n\t\t Department of Dermatology, University Medical Center Goettingen, 37075 Goettingen, Germany, kai.thoms@med.uni-goettingen.de"],["dc.contributor.affiliation","Schuler-Thurner, Beatrice; \t\t \r\n\t\t Department of Dermatology, Universitätsklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany, Beatrice.Schuler-Thurner@uk-erlangen.de\t\t \r\n\t\t Comprehensive Cancer Center Erlangen-European Metropolitan Area of Nuremberg (CCC ER-EMN), 91054 Erlangen, Germany, Beatrice.Schuler-Thurner@uk-erlangen.de"],["dc.contributor.affiliation","Ugurel, Selma; \t\t \r\n\t\t Department of Dermatology, University Hospital Essen, University Duisburg-Essen, 45147 Essen, Germany, Selma.Ugurel@uk-essen.de"],["dc.contributor.affiliation","Ulrich, Jens; \t\t \r\n\t\t Department of Dermatology, Harzklinikum Dorothea Christiane Erxleben, 06484 Quedlinburg, Germany, jens.ulrich@harzklinikum.com"],["dc.contributor.affiliation","Utikal, Jochen; \t\t \r\n\t\t Skin Cancer Unit, German Cancer Research Center (DKFZ), 68167 Heidelberg, Germany, Jochen.Utikal@umm.de\t\t \r\n\t\t Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg, 68167 Mannheim, Germany, Jochen.Utikal@umm.de"],["dc.contributor.affiliation","Weichenthal, Michael; \t\t \r\n\t\t Department of Dermatology, University Hospital Schleswig-Holstein, Campus Kiel, 24105 Kiel, Germany, mweichenthal@dermatology.uni-kiel.de"],["dc.contributor.affiliation","Ziller, Fabian; \t\t \r\n\t\t Department of Dermatology, DRK Krankenhaus Rabenstein, 09117 Chemnitz, Germany, Ziller.Fabian@drk-khs.de"],["dc.contributor.affiliation","Berking, Carola; \t\t \r\n\t\t Department of Dermatology, Universitätsklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany, Carola.Berking@uk-erlangen.de\t\t \r\n\t\t Comprehensive Cancer Center Erlangen-European Metropolitan Area of Nuremberg (CCC ER-EMN), 91054 Erlangen, Germany, Carola.Berking@uk-erlangen.de"],["dc.contributor.affiliation","Heppt, Markus; \t\t \r\n\t\t Department of Dermatology, Universitätsklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany, Markus.Heppt@uk-erlangen.de\t\t \r\n\t\t Comprehensive Cancer Center Erlangen-European Metropolitan Area of Nuremberg (CCC ER-EMN), 91054 Erlangen, Germany, Markus.Heppt@uk-erlangen.de"],["dc.contributor.author","Koch, Elias"],["dc.contributor.author","Petzold, Anne"],["dc.contributor.author","Wessely, Anja"],["dc.contributor.author","Dippel, Edgar"],["dc.contributor.author","Gesierich, Anja"],["dc.contributor.author","Gutzmer, Ralf"],["dc.contributor.author","Hassel, Jessica"],["dc.contributor.author","Haferkamp, Sebastian"],["dc.contributor.author","Hohberger, Bettina"],["dc.contributor.author","Heppt, Markus"],["dc.contributor.author","Thoms, Kai-Martin"],["dc.contributor.author","Kähler, Katharina"],["dc.contributor.author","Knorr, Harald"],["dc.contributor.author","Kreuzberg, Nicole"],["dc.contributor.author","Leiter, Ulrike"],["dc.contributor.author","Loquai, Carmen"],["dc.contributor.author","Meier, Friedegund"],["dc.contributor.author","Meissner, Markus"],["dc.contributor.author","Mohr, Peter"],["dc.contributor.author","Pföhler, Claudia"],["dc.contributor.author","Rahimi, Farnaz"],["dc.contributor.author","Schadendorf, Dirk"],["dc.contributor.author","Schell, Beatrice"],["dc.contributor.author","Schlaak, Max"],["dc.contributor.author","Terheyden, Patrick"],["dc.contributor.author","Schuler-Thurner, Beatrice"],["dc.contributor.author","Ugurel, Selma"],["dc.contributor.author","Ulrich, Jens"],["dc.contributor.author","Utikal, Jochen"],["dc.contributor.author","Weichenthal, Michael"],["dc.contributor.author","Ziller, Fabian"],["dc.contributor.author","Berking, Carola"],["dc.contributor.authorgroup","on behalf of the German Dermatologic Cooperative Oncology Group (DeCOG, Committee Ocular Melanoma)"],["dc.date.accessioned","2021-08-12T07:45:52Z"],["dc.date.available","2021-08-12T07:45:52Z"],["dc.date.issued","2021"],["dc.date.updated","2022-02-09T13:20:46Z"],["dc.description.abstract","Background: Since there is no standardized and effective treatment for advanced uveal melanoma (UM), the prognosis is dismal once metastases develop. Due to the availability of immune checkpoint blockade (ICB) in the real-world setting, the prognosis of metastatic UM has improved. However, it is unclear how the presence of hepatic and extrahepatic metastasis impacts the response and survival after ICB. Methods: A total of 178 patients with metastatic UM treated with ICB were included in this analysis. Patients were recruited from German skin cancer centers and the German national skin cancer registry (ADOReg). To investigate the impact of hepatic metastasis, two cohorts were compared: patients with liver metastasis only (cohort A, n = 55) versus those with both liver and extra-hepatic metastasis (cohort B, n = 123). Data were analyzed in both cohorts for response to treatment, progression-free survival (PFS), and overall survival (OS). The survival and progression probabilities were calculated with the Kaplan–Meier method. Log-rank tests, χ2 tests, and t-tests were performed to detect significant differences between both cohorts. Results: The median OS of the overall population was 16 months (95% CI 13.4–23.7) and the median PFS, 2.8 months (95% CI 2.5–3.0). The median OS was longer in cohort B than in cohort A (18.2 vs. 6.1 months; p = 0.071). The best objective response rate to dual ICB was 13.8% and to anti-PD-1 monotherapy 8.9% in the entire population. Patients with liver metastases only had a lower response to dual ICB, yet without significance (cohort A 8.7% vs. cohort B 16.7%; p = 0.45). Adverse events (AE) occurred in 41.6%. Severe AE were observed in 26.3% and evenly distributed between both cohorts. Conclusion: The survival of this large cohort of patients with advanced UM was more favorable than reported in previous benchmark studies. Patients with both hepatic and extrahepatic metastasis showed more favorable survival and higher response to dual ICB than those with hepatic metastasis only."],["dc.description.abstract","Background: Since there is no standardized and effective treatment for advanced uveal melanoma (UM), the prognosis is dismal once metastases develop. Due to the availability of immune checkpoint blockade (ICB) in the real-world setting, the prognosis of metastatic UM has improved. However, it is unclear how the presence of hepatic and extrahepatic metastasis impacts the response and survival after ICB. Methods: A total of 178 patients with metastatic UM treated with ICB were included in this analysis. Patients were recruited from German skin cancer centers and the German national skin cancer registry (ADOReg). To investigate the impact of hepatic metastasis, two cohorts were compared: patients with liver metastasis only (cohort A, n = 55) versus those with both liver and extra-hepatic metastasis (cohort B, n = 123). Data were analyzed in both cohorts for response to treatment, progression-free survival (PFS), and overall survival (OS). The survival and progression probabilities were calculated with the Kaplan–Meier method. Log-rank tests, χ2 tests, and t-tests were performed to detect significant differences between both cohorts. Results: The median OS of the overall population was 16 months (95% CI 13.4–23.7) and the median PFS, 2.8 months (95% CI 2.5–3.0). The median OS was longer in cohort B than in cohort A (18.2 vs. 6.1 months; p = 0.071). The best objective response rate to dual ICB was 13.8% and to anti-PD-1 monotherapy 8.9% in the entire population. Patients with liver metastases only had a lower response to dual ICB, yet without significance (cohort A 8.7% vs. cohort B 16.7%; p = 0.45). Adverse events (AE) occurred in 41.6%. Severe AE were observed in 26.3% and evenly distributed between both cohorts. Conclusion: The survival of this large cohort of patients with advanced UM was more favorable than reported in previous benchmark studies. Patients with both hepatic and extrahepatic metastasis showed more favorable survival and higher response to dual ICB than those with hepatic metastasis only."],["dc.identifier.doi","10.3390/cancers13133359"],["dc.identifier.eissn","2072-6694"],["dc.identifier.pii","cancers13133359"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/88565"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-448"],["dc.publisher","MDPI"],["dc.relation.eissn","2072-6694"],["dc.rights","https://creativecommons.org/licenses/by/4.0/"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0/"],["dc.title","Immune Checkpoint Blockade for Metastatic Uveal Melanoma: Patterns of Response and Survival According to the Presence of Hepatic and Extrahepatic Metastasis"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Journal for Immunotherapy of Cancer"],["dc.bibliographiccitation.volume","7"],["dc.contributor.author","Heppt, Markus V."],["dc.contributor.author","Amaral, Teresa"],["dc.contributor.author","Kähler, Katharina C."],["dc.contributor.author","Heinzerling, Lucie"],["dc.contributor.author","Hassel, Jessica C."],["dc.contributor.author","Meissner, Markus"],["dc.contributor.author","Kreuzberg, Nicole"],["dc.contributor.author","Loquai, Carmen"],["dc.contributor.author","Reinhardt, Lydia"],["dc.contributor.author","Utikal, Jochen"],["dc.contributor.author","Dabrowski, Evelyn"],["dc.contributor.author","Gesierich, Anja"],["dc.contributor.author","Pföhler, Claudia"],["dc.contributor.author","Terheyden, Patrick"],["dc.contributor.author","Thoms, Kai-Martin"],["dc.contributor.author","Zimmer, Lisa"],["dc.contributor.author","Eigentler, Thomas K."],["dc.contributor.author","Kirchberger, Michael C."],["dc.contributor.author","Stege, Henner M."],["dc.contributor.author","Meier, Friedegund"],["dc.contributor.author","Schlaak, Max"],["dc.contributor.author","Berking, Carola"],["dc.date.accessioned","2020-12-10T18:41:23Z"],["dc.date.available","2020-12-10T18:41:23Z"],["dc.date.issued","2019"],["dc.identifier.doi","10.1186/s40425-019-0800-0"],["dc.identifier.eissn","2051-1426"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/16952"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/77565"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.notes.intern","Merged from goescholar"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","e000333"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Journal for Immunotherapy of Cancer"],["dc.bibliographiccitation.volume","8"],["dc.contributor.author","Amaral, Teresa"],["dc.contributor.author","Kiecker, Felix"],["dc.contributor.author","Schaefer, Sarah"],["dc.contributor.author","Stege, Henner"],["dc.contributor.author","Kaehler, Katharina"],["dc.contributor.author","Terheyden, Patrick"],["dc.contributor.author","Gesierich, Anja"],["dc.contributor.author","Gutzmer, Ralf"],["dc.contributor.author","Haferkamp, Sebastian"],["dc.contributor.author","Uttikal, Jochen"],["dc.contributor.author","Berking, Carola"],["dc.contributor.author","Rafei-Shamsabadi, David"],["dc.contributor.author","Reinhardt, Lydia"],["dc.contributor.author","Meier, Friedegund"],["dc.contributor.author","Karoglan, Ante"],["dc.contributor.author","Posch, Christian"],["dc.contributor.author","Gambichler, Thilo"],["dc.contributor.author","Pfoehler, Claudia"],["dc.contributor.author","Thoms, Kai"],["dc.contributor.author","Tietze, Julia"],["dc.contributor.author","Debus, Dirk"],["dc.contributor.author","Herbst, Rudolf"],["dc.contributor.author","Emmert, Steffen"],["dc.contributor.author","Loquai, Carmen"],["dc.contributor.author","Hassel, Jessica C"],["dc.contributor.author","Meiss, Frank"],["dc.contributor.author","Tueting, Thomas"],["dc.contributor.author","Heinrich, Vanessa"],["dc.contributor.author","Eigentler, Thomas"],["dc.contributor.author","Garbe, Claus"],["dc.contributor.author","Zimmer, Lisa"],["dc.date.accessioned","2020-12-10T18:37:15Z"],["dc.date.available","2020-12-10T18:37:15Z"],["dc.date.issued","2019"],["dc.identifier.doi","10.1136/jitc-2019-000333"],["dc.identifier.eissn","2051-1426"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/76892"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG study in 380 patients"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","586"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Genes and Immunity"],["dc.bibliographiccitation.lastpage","590"],["dc.bibliographiccitation.volume","10"],["dc.contributor.author","Schoof, Nils"],["dc.contributor.author","von Bonin, Frederike"],["dc.contributor.author","Koenig, Inke R."],["dc.contributor.author","Moessner, R."],["dc.contributor.author","Krueger, Ulrich"],["dc.contributor.author","Reich, Kristian"],["dc.contributor.author","Berking, Carola"],["dc.contributor.author","Volkenandt, Matthias"],["dc.contributor.author","Ziegler, Andreas"],["dc.contributor.author","Boeckmann, L."],["dc.contributor.author","Kuschal, Christiane"],["dc.contributor.author","Thoms, K-M"],["dc.contributor.author","Kube, Dieter"],["dc.contributor.author","Emmert, Steffen"],["dc.date.accessioned","2018-11-07T11:24:52Z"],["dc.date.available","2018-11-07T11:24:52Z"],["dc.date.issued","2009"],["dc.description.abstract","Inherited promoter polymorphisms of the interleukin (IL)-10 gene resulting in altered IL-10 production may contribute to a genetic susceptibility for melanoma. We investigated the role of a haplotype from distal as well as proximal polymorphic sites [-7400InDel, -6752AT (rs6676671), -3538AT (rs1800890), -1087AG (rs1800896), -597AC (rs1800872)] of the IL-10 5'-flanking region in a hospital-based case-control study of 165 Caucasian patients with cutaneous melanoma from Germany in comparison with 162 healthy cancer-free Caucasian control participants from the same area matched by age. Using multivariate analysis for the number of nevi and skin type, the IL-10 'higher producing' haplotype ITAGC was found to be significantly associated with a reduced risk of developing melanoma ( adjusted P = 0.02). Although our findings need to be confirmed by independent and larger multicenter studies, we have described for the first time the association of distal gene variants of the IL-10 gene as an independent risk factor for melanoma. Genes and Immunity ( 2009) 10, 586-590; doi:10.1038/gene.2009.40; published online 21 May 2009"],["dc.description.sponsorship","Deutsche Forschungsgemeinschaft DFG [GRK1034]"],["dc.identifier.doi","10.1038/gene.2009.40"],["dc.identifier.isi","000269493400005"],["dc.identifier.pmid","19458621"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/56507"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Nature Publishing Group"],["dc.relation.issn","1466-4879"],["dc.title","Distal and proximal interleukin (IL)-10 promoter polymorphisms associated with risk of cutaneous melanoma development: a case-control study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]